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Abstract
OBJECTIVE: The objective of this selective evidence based medicine review is to 
determine whether or not a one or two dose regimen of dexamethasone (DEX) is a 
safe and effective treatment for asthma exacerbations in the pediatric population.
STUDY DESIGN: Review of three English language, primary randomized controlled 
trials (RCT) published from 2001-2008.
DATA SOURCES: Three RCTs examining the efficacy of DEX either in a single dose 
or one dose for two days, compared to a traditional five day regimen of prednisone 
(PRED). 
OUTCOMES MEASURED: The studies examined the number of relapses within 10 
days of using DEX or PRED, the number of subjects with unscheduled returns to the 
emergency department (ED) or other health care facility within 5 days, and episodes 
of emesis after administration of drug in the ED and at home within 5 days.
RESULTS: These studies concluded that both a single dose and two doses of DEX 
was no less effective than a five day regimen of PRED, specifically in regards to 
relapse rates and time to recovery. DEX did not lead to a higher rate of emesis than 
PRED either in the ED or within five days of initial treatment.
CONCLUSIONS: DEX is equally effective to PRED in the treatment of acute asthma 
exacerbations in pediatric patients, and does not lead to a greater rate of emesis 
within 5 days of treatment. Because DEX can be administered in a single dose or in 
a two day regimen, instead of the five day regimen required of PRED, patients may 
be more satisfied and have a higher compliance rate by using DEX.
KEY WORDS: Asthma, dexamethasone, pediatric
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Introduction
Asthma is a chronic airway disease characterized by inflammation, airway hyper-
reactivity, and reversible airway obstruction. It is likely that both an environmental and genetic 
component contribute to the etiology of the disease. Extrinsic factors contributing to asthma 
include atopic factors, environmental triggers, exercise, and early childhood infections. The 
airway of an asthmatic patient may include hyperplasia of the mucus glands, altered architecture 
of the airways that results from chronic inflammation and scarring, and bronchoconstriction.
Common symptoms include wheezing, coughing, and shortness of breath.
Approximately 25 million individuals in America have asthma, 7.1 million of which are 
children under 18 years of age 1, 2. Over nine percent of children in America suffer from asthma, 
and it is considered to be the most common chronic disease of childhood 1. Since 1980, the 
prevalence has been steadily increasing 1. Asthma is an extremely common disease that many 
physician assistants (PA) are likely to encounter on a regular basis. Both the management of 
asthma and the treatment of its exacerbations are within the scope of the PA practice.
The cost of managing asthma is similarly prodigious. The estimated cumulative cost of 
asthma, per year, is $56 billion 5. The average annual cost for an individual to manage their
asthma was found to be $3300 in medical expenses 5. The average cost of an ED visit for asthma 
exacerbation is $210, or up to $3102 if the patient is admitted 3.
Asthma exacerbations account for approximately 1.75 million visits to the ED a year 3. It 
is estimated that 2.57 million individuals had asthma in 2010, and the prevalence of asthma is 
currently at its highest, with an increased prevalence in pediatric patients 6. The number of ED 
visits per 100 individuals with asthma has not declined in the past ten years 6. 
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Many variants of asthma have been documented, including atopic and non-atopic types, 
exercise induced, occupational, and cough variant asthma. The onset of asthma is often in 
childhood, although adult-onset variants also exist. Atopy is the greatest risk factor for asthma, 
but other risk factors include obesity, urban city dwelling, and asthma in either or both parents 7. 
Pulmonary function testing is used to formally diagnose asthma. An expert panel has 
created a classification of asthma and a stepwise treatment approach 8. Treatment begins with 
patient education, such as recognizing exacerbations, and lifestyle modifications, including 
avoiding environmental triggers. Medical management can be divided into short and long term 
control modalities. Short-term control begins with a short acting beta agonist inhaler.
Ipratropium bromide is a possible adjunct. Long-term control begins with long acting beta 
agonist inhalers and inhaled corticosteroids; leukotriene agonists and mast cell stabilizers are 
adjuncts more commonly used in atopic asthma. Exacerbations are typically managed with oral 
or intravenous corticosteroids. Magnesium, oxygen, heliox, and airway management including 
intubation may be used in severe cases 7.
Objective
The objective of this selective EBM review is to determine whether or not a one or two 
dose regimen of dexamethasone is a safe and effective treatment for asthma exacerbations in the 
pediatric population
Methods
The population studied were children aged 2-18 presenting to the ED with a mild to 
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moderate asthma exacerbation with a history of asthma-like symptoms relieved with a beta-
antagonist.
The intervention in two of the studies was oral DEX once a day for two days. The third 
study (Altamimi) used a single dose of oral DEX. All of the studies used a five-day regimen of 
PRED as a control, although the exact dosing of these varied to a slight degree. Both the 
Greenberg and Altima studies used oral PRED twice daily for 5 days; the Qureshi study used 
oral PRED in the ED, followed by once daily PRED for 4 days.
The outcomes measured include unscheduled returns to the ED or relapse within 10 days, 
emesis with administration of drug, or within 5 days at home, return to baseline, days missed of 
school or work, length of stay, and hospital admission. The studies include three prospective, 
randomized trials, two of which were double-blinded and one (Qureshi) that was not.
The author found these three RCTs, all published in English in peer-reviewed journals 
between 2001 and 2008, using PubMed and OVID. The keywords used included asthma, 
dexamethasone, and pediatric. This author conducted the research, and selected the articles based 
on specific inclusion and exclusion data and comparability of data. Inclusion criteria included the 
focus of the article being patient oriented evidence that matters (POEM), and the articles being 
RCTs published after 2000. Exclusion criteria included any type of study which was not a RCT, 
or studies which involved a population younger than 2 or older than 18. The statistics reported in 
this review include the p-value, odds ratio (OR), confidence interval (CI), numbers needed to 
treat (NNT), numbers needed to harm (NNH) absolute risk reduction (ARR), relative risk 
reduction (RRR), relative benefit increase (RBI), and absolute benefit increase (ABI). Table 1 
includes the demographics of the included studies.
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Outcomes Measured
These studies measured the number of subjects with unscheduled returns to the ED or 
other medical facility, due to symptoms of asthma, within 5 or 10 days. The frequency of emesis 
was also measured; patients reported emesis via a patient self assessment score sheet, which was 
later reviewed with them by an investigator, or reported directly to an investigator on scheduled 
follow up, or emesis was observed in the ED with administration of the DEX or PRED. Other 
outcomes measured include return to baseline, missed days of school or work, length of stay in 
the ED, and admissions to the hospital.
Results
This review examined three RCTs including children aged 2-18 with a known history of 
asthma, and compared the intervention of a one or two day course of DEX compared to the 
traditional five day regimen of PRED. All studies included adolescent patients presenting to the
ED with an exacerbation of asthma.
The Altamimi study population included 110 children, and was conducted as a double 
blind RCT. The patients were randomized into two groups, one receiving a single dose of oral 
DEX (0.6 mg/kg to a maximum of 18 mg) and the other a five day regimen of oral PRED twice 
daily (1 mg/kg per dose to a maximum of 30 mg). The inclusion criteria included children aged 2 
to 16 presenting to the ED with exacerbations of mild to moderate asthma. All participants had a 
history of at least 1 prior episode suggesting asthma, which was treated with albuterol. Patients 
with severe asthma on presentation (peak expiratory flow reading (PEFR) less than 60%), 
complete recovery after salbutamol treatment, use of oral steroids in past 2 weeks, history of 
severe asthma exacerbation, prior intubation or admission to an intensive care unit (ICU), or 
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Table 1: Demographics of included studies 
Study and 
Type
# 
Pts
Age 
(yrs)
Inclusion criteria Exclusion criteria W/
D
Intervent
ions
Altamimi
(2006) 13
Double 
blind 
RCT
134 2-16 Children 2-16 y/o 
presenting to ED 
with exacerbation 
of mild to moderate 
asthma
At least 1 prior 
episode suggesting 
asthma, treated with 
albuterol
- Signs of severe asthma on 
presentation (PEFR less than 
60%, PIS of 10 or more), 
complete recovery after the first 
salbutamol therapy, use of oral 
steroids over the last 2 weeks, 
hx of severe asthma 
exacerbation, prior intubation or 
intensive care unit (ICU) 
admission for asthma, chronic 
lung disease, heart disease, 
neurological disorder, 
psychiatric disease, history of 
acute allergic reaction, active 
chickenpox, or herpes simplex 
infections
24 Single 
dose oral 
dexamet
hasone 
(0.6 
mg/kg to 
a 
maximu
m of 18 
mg)
Greenberg 
(2008) 14
Double 
blind 
RCT
108 2-18 Children aged 2 to 
18 presenting to the 
ED with an acute 
asthma 
exacerbation
All patients had two 
or more episodes of 
wheezing treated 
with a beta-
adrenergic agonist 
drug
Use of oral steroids in the past 
month, hx of intubation for a 
previous asthma exacerbation, 
Varicella exposure in the past 3 
weeks, Possible FB aspiration, 
Any chronic lung disease, 
Chronic heart, liver, or kidney 
disease, significant respiratory 
distress necessitating airway 
intervention, Previous 
enrollment in this study, no 
telephone for follow-up, two or 
more episodes of emesis after 
steroid given in ED
18 Oral 
dexamet
hasone 
(0.6 
mg/kg to 
a 
maximu
m of 16 
mg) once 
a day for 
2 days
Qureshi 
(2001) 15
RCT
628 2-18 Pts aged 2-18 years 
with a past hx of 
asthma defined as 2 
or more episodes of 
wheezing where 
beta-adrenergic 
agonists were used 
for treatment, 
required 2 or more 
albuterol tx in ED
Use of oral corticosteroids 4 
weeks prior to the current 
exacerbation, Hx of intubation, 
Varicella exposure in prior 3 
weeks, Concurrent stridor, 
Possibility of an intrathoracic 
FB, Chronic respiratory disease, 
Cardiac disease, Immediate 
airway intervention required
95 Oral 
dexamet
hasone 
(0.6 
mg/kg to 
a 
maximu
m of 18 
mg) qd 
for 2d
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chronic lung disease, neurological, psychiatric or heart disease, history of acute allergic reaction, 
herpes infection or active varicella infection, were excluded. Regarding compliance, only one 
patient in the PRED group and five in the DEX group received less than 80% of prescribed 
medicine. This was measured by counting the remaining medicine in the dispensed pill bottle; of 
note, those non-compliant in the DEX group missed only placebo doses as they received DEX in 
the ED.
Those in the DEX group had a shorter length of stay in the ED (3.5 + 1.93) compared to
those taking PRED (4.3 + 3.67 hours) (CI -1.8, 0.2). Each group required an average of 3.9 
salbutamol treatments (CI -0.51, 0.51), and the severity of asthma upon discharge was the same 
(CI -0.36, 0.56), as was the number of admissions (9% vs 13.4% respectively). Four subjects in 
the DEX group compared to one subject in the PRED group returned to the ED with persistent 
symptoms. A peak self-assessment score (PSAS) was used to quantify symptoms. The amount of 
days for PSAS to return to baseline was 5.21 for the DEX group and 5.22 for the PRED group 
(CI -0.7, 0.68). Two subjects in the PRED group withdrew from the study due to repeated 
emesis. On day five of follow up, one subject from the PRED and none from the DEX group 
reported emesis, and the NNH was -100, so that it would take 100 patients receiving DEX to
have one fewer episode of emesis (RRR=2.664, ARR=0.0477). The primary outcome showed 
that DEX was slightly more effective in preventing relapses, and the NNT was 21, so that for 
every 21 patients given DEX, one more would have relapse prevention over PRED (RRI=-1, 
ARI=-0.01). Data from the intent to treat analysis is presented in Table 2.
The Greenberg study population included 89 children, and was conducted as a double 
blind RCT. The patients were randomized into two groups, one receiving oral DEX (0.6 mg/kg 
to a maximum of 16 mg) once a day for two days, and the other a five day regimen of oral PRED 
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twice daily (1 mg/kg per dose to a maximum of 30 mg). The inclusion criteria included children 
aged 2 to 18 presenting to the ED with an acute asthma exacerbation, and a history of two or 
more episodes of wheezing treated with a beta-adrenergic agonist drug. Patients with oral steroid 
use in the past month, history of intubation, varicella exposure in prior 3 weeks, possible foreign 
body aspiration, chronic heart, liver, kidney or lung disease, symptoms necessitating intubation, 
prior enrollment in this study, no telephone for follow up, or two or more episodes of emesis in 
the ED after steroid administration, were excluded from the study. No patients necessitated 
exclusion due to non-compliance.
Patients from both the DEX and PRED group did not differ in the quantity of breathing 
treatments in the prior 24 hours preceding presentation to ED. Presenting vital signs, including 
temperature, heart rate, respiratory rate, systolic blood pressure and pulse oximetry, did not differ 
between the two groups. A pediatric asthma score (PAS), used to gauge severity of asthma, was 
higher on presentation in the DEX group (P 0.003). The primary outcome studied was need for 
unscheduled follow up. There was no significant difference found in this outcome: 8 patients in 
the DEX group (16%) and 3 in the PRED group (8%) required unscheduled follow-up (P 0.27).
The analysis showed DEX to be as or more effective than PRED in preventing relapse (RRR= 
0.50, ARR=0.08, NNT=13). Five patients in the DEX group (10%) and 7 in the PRED group 
(18%) had emesis in the ED (P 0.24). DEX may infer an advantage in preventing adverse effects 
(RRI=0.44, ARI=-0.08, NNH=-12). Data from the intent to treat analysis is in Table 3.
The Qureshi trial was a RCT, which was not double blinded because DEX tablets were 
used versus PRED suspension or tablets. Because the decision to return for treatment after being 
discharged from the ED was solely based on the parents’ discretion, potential investigator bias 
was minimized. This study included children aged 2 to 18 presenting to the ED with an acute 
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asthma exacerbation, and with a history of asthma, defined by two or more episodes of wheezing 
treated with beta-adrenergic agonists; also the children included required 2 or more albuterol 
nebulizer treatments in the ED. Children with use of oral steroids in the prior month, varicella 
exposure in prior 3 weeks, history of intubation or need for immediate airway intervention, 
concurrent stridor, possibility of inhaled foreign body, or chronic respiratory or cardiac disease, 
were excluded from the trial.
The patients were randomized into two groups, one receiving oral DEX (0.6 mg/kg to a 
maximum of 18 mg) once a day for two days, and the other receiving oral PRED (2 mg/kg per 
dose to a maximum of 60 mg) in the ED, followed by a once daily dose of PRED (1 mg/kg/dose) 
for four more days. Of note, compliance did differ between the two groups. In the PRED group, 
6 parents did not purchase the PRED following discharge due to “insufficient funds” and because 
“I forgot”. Only one parent in the DEX group failed to administer the second dose of DEX to 
their child. Significantly more children were excluded from enrollment in the PRED group than 
in the DEX group due to observed emesis in the ED.
Patients in both groups were found to be equivalent in demographics and severity of 
asthma upon presentation. Data reported from the children’s parents revealed no significant 
differences between oral beta-adrenergic agonists and inhaled corticosteroid use in the 24 hours 
preceding presentation to the ED. The number of nebulizer treatments administered in the ED 
was equal between groups. The total time spent in the ED and severity of asthma upon discharge 
did not differ (P values of 0.30, 0.09 and 0.35 for nebulizer use in ED, time in ED and severity of 
asthma upon discharge, respectively; all with a 95% CI). No significant difference in relapse 
rates between the two groups was found (DEX 7.4%, PRED 6.9%, OR of 1.08 and CI of 0.55 to 
2.08 with P value of 0.84). DEX was found to be at least as effective in preventing relapse. There 
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was not a significant difference in admission in those who relapsed. An intention to treat 
analysis, considering relapse, favored the DEX group, however the difference was not of 
significant value (DEX 8.7%, PRED 13.5%, OR 0.61, CI 0.35 to 1.05, P of 0.07; NNT=200, 
ARR=-0.005). A larger amount of children in the PRED group missed 2 or more days of school, 
and their parents 1 or more days of work (19.5% vs 13.2%; P=0.05). The PRED group also had a 
higher rate of emesis at home (NNH=-50.0, ARI=-0.02), and fewer parents were compliant with 
administration of PRED at home, as measured by refills filled. Data from the intent to treat 
analysis is presented in Table 4.
The main adverse drug reaction to DEX was emesis, which was no greater than in those 
taking PRED. As detailed in the Qureshi group, days missed of work or school were found to be 
higher in the PRED group. None of the studies found a severe adverse reaction to DEX.
Table 2: Single dose DEX vs five day regimen of PRED
Study P value CER EER RRR ARR NNT RRI ARI NNH
Altamimi 0.05 0.0179 0.0656 2.664 0.0477 21 -1 -0.01 -100
Table 3: Two day single dose DEX vs five day regimen of twice a day PRED
Study P value CER EER RRR ARR NNT RRI ARI NNH
Greenberg 0.05 0.08 0.16 0.50 0.08 13 0.44 -0.08 -12
Table 4: Two day single dose DEX vs five day regimen of daily PRED
Study P value OR CER EER RRR ARR NNT RRI ARI NNH
Qureshi 0.07 1.08 0.074 0.069 -0.068 -0.005 200 -0.50 -0.02 -50
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Discussion 
PRED is the drug recommended for asthma exacerbations by the National Institutes of
Health 9, and has been classically used despite an array of other corticosteroids being available.
The half-life of PRED is 12 hours, necessitating a five-day regimen, often given twice daily, 
which inherently raises some compliance issues. Comparatively, the half-life of DEX is 36 to 72 
hours, and it is approximately six times more potent than PRED. All three of the reviewed trials 
consistently showed DEX to be as effective as PRED, with a slightly lower rate of emesis, and 
an improved rate of parental compliance when measured. Furthermore, DEX administered at a 
dose of 0.6 mg/kg has been studied at length in the treatment of croup, without report of serious 
adverse drug reactions 11. Regarding cost of medication, a study found that two days worth of 
DEX was more affordable for patients than five days worth of PRED, and use of DEX in acute 
asthma exacerbations also lead to decreased secondary costs 12. Patients with compliance issues 
would theoretically do better with either a single or two-day, one time dose of DEX.
This review investigated a population aged 2-18 but not adult patients. It also did not 
investigate severe asthma exacerbations or those requiring intravenous steroids. The population 
size was relatively large in the Qureshi study but not so in the other two studies, and the Qureshi 
study was not double blinded. 
Conclusion
This review showed that DEX is both safe and effective as a treatment modality for acute 
asthma exacerbations in children. The relapse rate within five to ten days was not significantly 
greater in those taking a one or two day regimen of DEX, compared to those taking a five day 
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regimen of PRED. Use of DEX may lead to better compliance and patient satisfaction 9.
Although more, larger studies would further elucidate the findings of this review, it may be 
reasonable to enact treatment with a one or two day regimen of DEX in asthma exacerbations, 
particularly in patients in which compliancy or affordability of medications is an issue.
Aside from larger studies, other pertinent issues warrant further examination. First, more 
studies examining a single dose of DEX would be helpful, as this is ideal in regards to patient 
compliance and satisfaction. Second, the long-term safety of DEX, especially in repeated doses 
to treat asthma in adolescents, should be examined. Finally, trials examining other patient 
populations and severities of asthma should be conducted. These could include the same 
treatment in adult patients, pregnant patients, patients with more severe presentations of asthma 
exacerbation, including those necessitating immediate airway interventions, and patients with a 
concurrent history of chronic heart, lung, liver or kidney disease.
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